These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 37491358)
1. Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic. Bucci M; Bluma M; Savitcheva I; Ashton NJ; Chiotis K; Matton A; Kivipelto M; Di Molfetta G; Blennow K; Zetterberg H; Nordberg A Transl Psychiatry; 2023 Jul; 13(1):268. PubMed ID: 37491358 [TBL] [Abstract][Full Text] [Related]
2. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort. Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN; Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591 [TBL] [Abstract][Full Text] [Related]
3. Performance of plasma Aβ42/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status. Bun S; Ito D; Tezuka T; Kubota M; Ueda R; Takahata K; Moriguchi S; Kurose S; Momota Y; Suzuki N; Morimoto A; Hoshino Y; Seki M; Mimura Y; Shikimoto R; Yamamoto Y; Hoshino T; Sato Y; Tabuchi H; Mimura M Alzheimers Res Ther; 2023 Sep; 15(1):149. PubMed ID: 37667408 [TBL] [Abstract][Full Text] [Related]
4. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population. Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397 [TBL] [Abstract][Full Text] [Related]
5. Comparing tau status determined via plasma pTau181, pTau231 and [ Tissot C; Therriault J; Kunach P; L Benedet A; Pascoal TA; Ashton NJ; Karikari TK; Servaes S; Lussier FZ; Chamoun M; Tudorascu DL; Stevenson J; Rahmouni N; Poltronetti NM; Pallen V; Bezgin G; Kang MS; Mathotaarachchi SS; Wang YT; Fernandez Arias J; Ferreira PCL; Ferrari-Souza JP; Vanmechelen E; Blennow K; Zetterberg H; Gauthier S; Rosa-Neto P EBioMedicine; 2022 Feb; 76():103837. PubMed ID: 35134647 [TBL] [Abstract][Full Text] [Related]
6. Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients. Mendes AJ; Ribaldi F; Lathuiliere A; Ashton NJ; Zetterberg H; Abramowicz M; Scheffler M; Assal F; Garibotto V; Blennow K; Frisoni GB Alzheimers Res Ther; 2024 May; 16(1):110. PubMed ID: 38755703 [TBL] [Abstract][Full Text] [Related]
7. A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer's Disease Continuum. Coomans EM; Verberk IMW; Ossenkoppele R; Verfaillie SCJ; Visser D; Gouda M; Tuncel H; Wolters EE; Timmers T; Windhorst AD; Golla SSV; Scheltens P; van WM; Flier D; van Berckel BNM; Teunissen CE J Nucl Med; 2023 Mar; 64(3):437-443. PubMed ID: 36229187 [TBL] [Abstract][Full Text] [Related]
13. Pathophysiology characterization of Alzheimer's disease in South China's aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS). Liu Z; Shi D; Cai Y; Li A; Lan G; Sun P; Liu L; Zhu Y; Yang J; Zhou Y; Guo L; Zhang L; Deng S; Chen S; Yu X; Chen X; Zhao R; Wang Q; Ran P; Xu L; Zhou L; Sun K; Wang X; Peng Q; Han Y; Guo T Alzheimers Res Ther; 2024 Apr; 16(1):84. PubMed ID: 38627753 [TBL] [Abstract][Full Text] [Related]
14. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy. Chouliaras L; Thomas A; Malpetti M; Donaghy P; Kane J; Mak E; Savulich G; Prats-Sedano MA; Heslegrave AJ; Zetterberg H; Su L; Rowe JB; O'Brien JT J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):651-658. PubMed ID: 35078917 [TBL] [Abstract][Full Text] [Related]
15. Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study. Pérez-Grijalba V; Arbizu J; Romero J; Prieto E; Pesini P; Sarasa L; Guillen F; Monleón I; San-José I; Martínez-Lage P; Munuera J; Hernández I; Buendía M; Sotolongo-Grau O; Alegret M; Ruiz A; Tárraga L; Boada M; Sarasa M; Alzheimers Res Ther; 2019 Dec; 11(1):96. PubMed ID: 31787105 [TBL] [Abstract][Full Text] [Related]
16. The dynamics of plasma biomarkers across the Alzheimer's continuum. Guo Y; Shen XN; Wang HF; Chen SD; Zhang YR; Chen SF; Cui M; Cheng W; Dong Q; Ma T; Yu JT Alzheimers Res Ther; 2023 Feb; 15(1):31. PubMed ID: 36750875 [TBL] [Abstract][Full Text] [Related]
17. Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage. Asken BM; Elahi FM; La Joie R; Strom A; Staffaroni AM; Lindbergh CA; Apple AC; You M; Weiner-Light S; Brathaban N; Fernandes N; Karydas A; Wang P; Rojas JC; Boxer AL; Miller BL; Rabinovici GD; Kramer JH; Casaletto KB J Alzheimers Dis; 2020; 78(1):265-276. PubMed ID: 32986672 [TBL] [Abstract][Full Text] [Related]
18. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Cicognola C; Janelidze S; Hertze J; Zetterberg H; Blennow K; Mattsson-Carlgren N; Hansson O Alzheimers Res Ther; 2021 Mar; 13(1):68. PubMed ID: 33773595 [TBL] [Abstract][Full Text] [Related]
19. Combination of plasma amyloid beta Verberk IMW; Thijssen E; Koelewijn J; Mauroo K; Vanbrabant J; de Wilde A; Zwan MD; Verfaillie SCJ; Ossenkoppele R; Barkhof F; van Berckel BNM; Scheltens P; van der Flier WM; Stoops E; Vanderstichele HM; Teunissen CE Alzheimers Res Ther; 2020 Sep; 12(1):118. PubMed ID: 32988409 [TBL] [Abstract][Full Text] [Related]